US Patent

US12005051 — Topical roflumilast formulation having improved delivery and plasma half life

Method of Use · Assigned to Arcutis Biotherapeutics Inc · Expires 2037-06-07 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using roflumilast, specifically a topically administered formulation with improved delivery and plasma half-life.

USPTO Abstract

The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and/or hexylene glycol.

Drugs covered by this patent

Daliresp (ROFLUMILAST) · Arcutis

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3970`	—	Daliresp
`U-3748`	—	Daliresp
`U-4301`	—	Daliresp
`U-4203`	—	Daliresp

Patent Metadata

Patent number: US12005051
Jurisdiction: US
Classification: Method of Use
Expires: 2037-06-07
Drug substance claim: No
Drug product claim: No
Assignee: Arcutis Biotherapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.